Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

European Journal of Clinical Pharmacology

Volumn 68, Issue 11, 2012, Pages 1501-1508

  Statkevich, Paul ^a   Kosoglou, Teddy ^a   Preston, Richard A ^b,c   Kumar, Bharath ^a   Xuan, Fengjuan ^a   Trusley, Craig ^a   Schiller, James E ^a   Langdon, Ronald B ^a   Cutler, David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

Hepatic impairment; PAR 1 antagonist; Pharmacokinetics; SCH 530348; Thrombin receptor antagonist; Vorapaxar

Indexed keywords

DRUG METABOLITE; IBUPROFEN; M 20; PROTEINASE ACTIVATED RECEPTOR 1; UNCLASSIFIED DRUG; VORAPAXAR;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOODY DIARRHEA; BODY HEIGHT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ESOPHAGUS VARICES; FEMALE; GASTRIC BANDING; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RHINOPHARYNGITIS; SEX DIFFERENCE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; WEAKNESS;

AGED; BIOTRANSFORMATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HALF-LIFE; HEPATIC INSUFFICIENCY; HUMANS; INTESTINAL ABSORPTION; LACTONES; LIVER FAILURE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; SEVERITY OF ILLNESS INDEX;

EID: 84867573817     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1269-7     Document Type: Article

References (27)

1. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapyI: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106
2. CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339 (Pubitemid 26383772)
3. Dogne JM, de Leval X, Benoit P, Delarge J, Masereel B, David JL (2002) Recent advances in antiplatelet agents. Curr Med Chem 9:577-589 (Pubitemid 34436435)
4. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, for the CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706-1717
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502 (Pubitemid 32758501)
6. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, for the TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015 (Pubitemid 350106708)
7. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW (1999) Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 96:11189-11193 (Pubitemid 29487356)
8. Chackalamannil S (2003) G-protein couple receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents. Curr Top Med Chem 3:1115-1123
9. Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P (2010) Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 17:156-164
10. Shinohara Y, Goto S, Doi M, Jensen P (2010) Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis. doi: 10.1016/j. jstrokecerebrovasdis.2010.09.005
11. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA, for the TRA-PCI Investigators (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373:919-928
12. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E, for the TRA 2°P-TIMI 50 Investigators (2009) Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial. Am Heart J 158:335-341
13. TRACER Executive and Steering Committees (2009) The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial: study design and rationale. Am Heart J 158:327-334
14. Kosoglou T, Reyderman L, Tiessen RG, van Vliet AA, Fales RR, Keller R, Yang B, Cutler DL (2012) Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol 68:249-258
15. Kosoglou T, Reyderman L, Kasserra C, Jennings LK, Young S, Xuan F, Pei J, Maxwell SE, Meehan AG, Cutler DL (2012) No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol 68:291-300
16. Ghosal A, Lu X, Penner N, Gao L, Ramanathan R, Chowdhury SK, Kishnani NS, Alton KB (2011) Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos 39:30-38
17. Statkevich P, Kosoglou T, Kumar B, Li J, Xuan F, Wang Z, Meehan AG, Cutler DL (2012) Pharmacokinetics of vorapaxar and its metabolite SCH 2046273 (M20) following oral administration in healthy Chinese and US subjects (abstract). Clin Pharmacol Ther (in press)
18. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649
20. McLean AJ, Morgan DJ (1991) Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 21:42-69
21. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A (1998) Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 34:33-46 (Pubitemid 28123378)
22. Sulsa GM, Atkinson AJ (2007) Effect of liver disease on pharmacokinetics. In: Atkinson AJ Jr, Abernethy DR, Daniels CE, Dedrick R, Markey SP (eds) Principles of clinical pharmacology, 2nd edn. Academic Press, New York, pp 73-87
23. Adedoyin A, Arns PA, Richards WO, Wilkinson GR, Branch RA (1998) Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 64:8-17 (Pubitemid 28377325)
24. Horak J, White J, Harris AL, Verrill M, Carmichael J, Holt A, Cantarini M, Macpherson M, Swaisland A, Swaisland H, Twelves C (2011) The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol 68(6):1485-1495
25. Weil A, Martin P, Smith R, Oliver S, Langmuir P, Read J, Molz KH (2010) Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet 49:607-618
26. Bruderer S, Detishin V, Tsvitbaum N, Dingemanse J (2011) Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan. Br J Clin Pharmacol 71:52-60
27. Zhang C, Thabut D, Kamath PS, Shah VH (2011) Oesophageal varices in cirrhotic patients: from variceal screening to primary prophylaxis of the first oesophageal variceal bleeding. Liver Int 31:108-119